Publication: 4156

Publication: 4156

Alliance A021602: Phase III, Double Blinded Study of Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression on Prior Therapy (CABINET)

URL

Google Scholar

Citation:: Ann Oncol vol 34 (suppl 2) S1292, abstr LBA53

Meeting Instance:: ESMO 2023
Year:: 2023
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 4434

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Exelixis
Grants:: U10CA180821, U10CA180882; U10CA180820 (SWOG), U10CA180868 (NRG), U10CA180888 (SWOG)

Corr. Author:
Authors:: Jennifer A Chan Susan Geyer Fang-Shu Ou Michael Knopp Spencer Behr Tyler Zemla Jared Acoba Ardaman Shergill Edward M Wolin Thorvardur R Halfdanarson Nikolaos A Trikalinos Bhavana Konda Namrata Vijayvergia Arvind Dasari Jonathan R Strosberg Elise C Kohn Matthew H Kulke Eileen M O'Reilly Jeffrey A Meyerhardt

Networks:: CA824, FL065, HAWAII, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, NY021

Study: Alliance-A021602
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: